Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis (DEXSAR)
Primary Purpose
Sarcoidosis
Status
Unknown status
Phase
Phase 3
Locations
Netherlands
Study Type
Interventional
Intervention
Dexamethasone
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Sarcoidosis
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of sarcoidosis, confirmed by histology or cytology
- Age 18-60 years
- No affected organ requiring high dose immunosuppressive therapy
- Short Form - 36 subscale physical functioning score < 70 points
Exclusion Criteria:
- Allergy to corticosteroids
- Diagnosis of glaucoma, osteoporosis, history of fractures
- History of gastric ulcera in the past 12 months
- Current use of Non Steroidal Anti Inflammatory Drug without co-prescription of Proton Pump Inhibitor
- Current use of carbamazepin, fenytoin, rifampicin
- Obesity (BMI > 30)
- Pregnancy of lactation
Sites / Locations
- St Antonius HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Dexamethasone 1 mg
Placebo
Arm Description
Dexamethasone 1 mg per day, for 180 days
Placebo tablet, for 180 days
Outcomes
Primary Outcome Measures
Change in health-related quality of life versus baseline
The primary outcome measure is the change in health-related quality of life compared with baseline.
Secondary Outcome Measures
Full Information
NCT ID
NCT01920919
First Posted
August 7, 2013
Last Updated
November 18, 2014
Sponsor
St. Antonius Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01920919
Brief Title
Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis
Acronym
DEXSAR
Study Type
Interventional
2. Study Status
Record Verification Date
November 2014
Overall Recruitment Status
Unknown status
Study Start Date
June 2013 (undefined)
Primary Completion Date
August 2016 (Anticipated)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
St. Antonius Hospital
4. Oversight
5. Study Description
Brief Summary
This trial examines whether low grade suppression of the initial inflammatory process of sarcoidosis by intervention with low-dose dexamethasone therapy achieves significant alleviation of (sub-)acute symptoms, improvement in quality of life, increase in work productivity, and whether this intervention prevents disease progression and reduces total health-care costs.
Detailed Description
The orphan disease sarcoidosis causes a major reduction in quality of life and loss of work productivity, especially in young adults. Most patients are diagnosed between the age of 20-40 years. In sarcoidosis, multiple organs are affected by inflammation; the cause of the disease is unknown and no curative medication exists. Sarcoidosis invalidates the lives of most patient for many years.
Although curative (pharmaco) therapy is not on hand, immunosuppressive drugs may control the symptoms of the disease. These symptoms are caused by the inflammation in multiple organs, foremost the lungs and the lymphoid system. However, 90% of the sarcoidosis patients receives no immunosuppressive medication at all during the first months after diagnosis, even though the immune system is then highly activated and patients suffer from severe complaints like malaise, fatigue and pain. This wait-and-see policy is common international practice, but scientific grounds and official guidelines are lacking.
This project examines whether low grade suppression of the initial inflammatory process of sarcoidosis by intervention with low-dose dexamethasone therapy achieves significant alleviation of (sub-)acute symptoms, improvement in quality of life, increase in work productivity, and whether this intervention prevents disease progression and reduces total health-care costs.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sarcoidosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
76 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Dexamethasone 1 mg
Arm Type
Experimental
Arm Description
Dexamethasone 1 mg per day, for 180 days
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo tablet, for 180 days
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Change in health-related quality of life versus baseline
Description
The primary outcome measure is the change in health-related quality of life compared with baseline.
Time Frame
0, 3, 6, 12, 18, 24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of sarcoidosis, confirmed by histology or cytology
Age 18-60 years
No affected organ requiring high dose immunosuppressive therapy
Short Form - 36 subscale physical functioning score < 70 points
Exclusion Criteria:
Allergy to corticosteroids
Diagnosis of glaucoma, osteoporosis, history of fractures
History of gastric ulcera in the past 12 months
Current use of Non Steroidal Anti Inflammatory Drug without co-prescription of Proton Pump Inhibitor
Current use of carbamazepin, fenytoin, rifampicin
Obesity (BMI > 30)
Pregnancy of lactation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Roeland Vis
Phone
0031 30 609 2612
Email
r.vis@antoniusziekenhuis.nl
Facility Information:
Facility Name
St Antonius Hospital
City
Nieuwegein
ZIP/Postal Code
3430 EM
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Roeland Vis
12. IPD Sharing Statement
Learn more about this trial
Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis
We'll reach out to this number within 24 hrs